To determine whether the performance of cytoreductive surgery and HIPEC results in a survival advantage in patients with PC from colorectal origin when compared to standard palliative treatment.
To determine morbidity and mortality associated with cytoreductive surgery and HIPEC for peritoneal carcinomatosis from colorectal origin.
To evaluate different study designs used to investigate the management of peritoneal carcinomatosis, and to identify the limitations in these study designs. This information will be discussed in the “implications for research” section.
This is a protocol.